Boardroom Alpha
10-K primary document
ABT · Annual Report (Form 10-K) · Filed February 20, 2026

Abbott Laboratories10-K exhibit

exhibit23eyconsent11.htm
Document

Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1)    Registration Statement No. 333‑158782 on Form S‑8 for the Abbott Laboratories 2009 Incentive Stock Program;

2)    Registration Statement Nos. 333‑74220, 333‑102179, 333‑124851, 333‑153200, 333‑169886, 333‑204773, 333-227803, and 333-251334 on Form S‑8 for the Abbott Laboratories Deferred Compensation Plan;

3)    Registration Statement Nos. 33‑26685, 33‑50452, 33‑51585, 33‑56897, 33‑65127, 333‑19511, 333‑43383, 333‑69579, 333‑93257, 333‑74224, 333‑102180, 333‑109253, 333‑124849, 333‑141116, 333‑153198, 333‑169888, 333‑204772, 333-227802 and 333-251335 on Form S‑8 for the Abbott Laboratories Stock Retirement Program and Trusts;

4)    Registration Statement No. 333-271595 on Form S-3;

5)    Registration Statement Nos. 333‑212002 and 333-216141 on Form S‑4;

6)    Post-Effective Amendment on Form S‑8 to Registration Statement No. 333‑212002 on Form S‑4 for the St. Jude Medical, Inc. 2007 Stock Incentive Plan, as Amended and Restated (2014) and the Thoratec Corporation Amended and Restated 2006 Incentive Stock Plan;

7)    Registration Statement Nos. 333‑215423 and 333-227804 on Form S‑8 for the Management Savings Plan (f/k/a the St. Jude Medical, Inc. Management Savings Plan), as amended and restated effective January 1, 2016; and

8)    Registration Statement No. 333-217540 on Form S-8 for the Abbott Laboratories 2017 Incentive Stock Program and the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees

of our reports dated February 20, 2026, with respect to the consolidated financial statements, the financial statement schedule and the effectiveness of internal control over financial reporting of Abbott Laboratories and subsidiaries included in this Annual Report (Form 10‑K) of Abbott Laboratories and subsidiaries for the year ended December 31, 2025.

/s/ Ernst & Young LLP
Chicago, Illinois
February 20, 2026



Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer